European Commission Grants Marketing Authorization for Gileads Harvoni LedipasvirSofosbuvir the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4

OnceDaily Single Tablet Regimen Eliminates the Need for Interferon and Ribavirin for Patients with Genotype 1 and 4 Hepatitis C without Cirrhosis or with Compensated Cirrhosis Gilead Sciences Inc. NasdaqGILD today announced tha...